Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain
Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain
(Reuters) - A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis ...
Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan's Ci:z
Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan's Ci:z
Add another Big Pharma company to the wheeling and dealing in consumer health.
AbbVie rheumatoid arthritis drug succeeds in late stage trial
AbbVie rheumatoid arthritis drug succeeds in late stage trial
NEW YORK (Reuters) - AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain and quality of life compa...
AstraZeneca digs deeper into cancer with Innate stake
AstraZeneca digs deeper into cancer with Innate stake
LONDON/PARIS (Reuters) - AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.
Takeda buys stake in Enterome’s microbiome Crohn’s drug
Takeda buys stake in Enterome’s microbiome Crohn’s drug
Takeda has paid $50 million (€44 million) upfront to co-develop Enterome’s early-phase Crohn’s disease candidate EB8018.
U.S. scientists create new drug to sustain oxygen-starved hearts
U.S. scientists create new drug to sustain oxygen-starved hearts
SAN FRANCISCO, Oct.
Phase II trial of capmatinib demonstrates positive results in NSCLC
Phase II trial of capmatinib demonstrates positive results in NSCLC
Novartis said that the phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) has demonstrated positive results in patients with MET mutated advanced non-small cell lun...
Molecule-level 'CT scans' could lead to faster drug discovery
Molecule-level 'CT scans' could lead to faster drug discovery
Scientists like to use x-rays when determining chemical structures to develop drugs, but it's an agonizingly slow process.
No sweat required: Team finds hypertension treatment that mimics effect of exercise
No sweat required: Team finds hypertension treatment that mimics effect of exercise
Hypertension researchers at The University of Toledo have shown that by increasing the body's supply of beta hydroxybutyrate, a chemical produced predominantly by the liver, it is possible to regu...
Omega-3 Fatty Acids: Health Benefits And Sources
Omega-3 Fatty Acids: Health Benefits And Sources
In recent decades, researchers and the general public have placed more significance on omega-3 fatty acids, consuming them from dietary sources or looking into fish oil supplements.
Chinese pharmacists fined $1.3 billion for a fake vaccine
Chinese pharmacists fined $1.3 billion for a fake vaccine
The regulator also imposed a ban on working in the pharmaceutical sector for 14 managers.
Cost of blood pressure drug surges in U.S. after recall
Cost of blood pressure drug surges in U.S. after recall
NEW YORK (Reuters) - Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug’s sup...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand